MOBERG DERMA ACQUIRES PHARMACEUTICAL PROJECTS FROM ZELMIC

Moberg Derma AB today announces the acquisition of two pharmaceutical projects in preclinical phase from Zelmic AB (Lund, Sweden). Zelmic will assist Moberg Derma in the future development of the projects. The two companies also agreed on a long term collaboration on future development projects. Financial terms were not disclosed.

“We have worked with the Zelmic team for some time and are impressed by their innovation and development capabilities. These projects broaden Moberg Derma’s portfolio and add product candidates of substantial value”, says Peter Wolpert, CEO of Moberg Derma AB and adds. “This is our first acquisition. External opportunities and acquisitions are an integral part of our expansion strategy.”

“It is invaluable for Zelmic to collaborate with Moberg Derma who is a commercially focused partner. Moberg Derma has the capacity to further develop and commercialize our projects. The two companies has complementing know-how and experience which provide considerable synergies”, says Åke Lindahl, CEO of Zelmic AB.

Tags: